Cell and Life Therapeutics announces that Prof.Ankur Jain in MIT Biology Dept., joins the Company as CSO and the opening of its US company.

Cell and Life Therapeutics is developing next-generation small-molecule medicines to target the RNA cycle for treating neurodegenerative and oncology disorders. In collaboration with Jubilant Biosys, Cell and Life Therapeutic has established “STAR (Small-molecule TArgeting RNA biology)” library platform. Recently Cell and Life Therapeutic has selected a preclinical candidate for muscle atrophy diseases and potentially immune-oncology modulators. Cell […]

EmstoPA has received the Regulatory Endorsement of Development Program by British MHRA

We are proud to announce that our client EmstoPA has received the Regulatory Endorsement of Development Program by British MHRA and US FDA: The Medicines & Healthcare Products Regulatory Agency have recently reviewed and endorsed EmstoPA’s Plan, providing excellent feedback on each aspect. FDA has also reviewed and provided positive feedback for EmstoPA development plan EmstoPA has […]

Our client BrainEver Receives FDA Orphan Drug Designation for BREN-02, (human recombinant Engrailed 1) for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

BREN-02 is expected to be administered in clinical trials in ALS patients in the second half of 2021, subject to preclinical toxicity results and regulatory review. Preclinical studies have shown that the homeoprotein hEN1 is essential for the survival and maintenance of spinal cord alpha motor neurons that innervate muscles throughout the body. The FDA […]